Found 278 matching trials
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
PHASE2The goal of this prospective study is to explore the safety and preliminary...
Location
Fudan University Shanghai Cancer Center
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
PHASE1The goal of this randomized clinical trial is to learn if topical treatment...
Location
Genesis Cancer and Blood Institute
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
PHASE1This is an open-label, two-arm, Phase I, dose escalation study to evaluate ...
Location
GSK Investigational Site
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
PHASE1This is a phase I study of second primary tumor prevention in early stage (...
Location
Emory University Winship Cancer Institute
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
PHASE1BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multipl...
Status
Active Not Recruiting
Location
University of Alabama
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
PHASE1The purpose of this randomized study is to determine the safety and efficac...
Location
Valkyrie Clinical Trials
Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression
PHASE2There have been reports suggesting that continuous administration of epider...
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
PHASE1This study will treat patients with advanced NSCLC with EGFR or HER2 mutati...
Status
Active Not Recruiting
Location
University of California, San Diego (UCSD) - Moores Cancer Center
CIML NK Cell in Head & Neck Cancer
PHASE1This research study is evaluating the safety and efficacy of a combination ...
Location
Dana Farber Cancer Institute
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
PHASE2This is a multicenter, single-arm, phase II clinical study evaluating the e...
Status
Enrolling By Invitation
Location
The First People's Hospital of Foshan